AVXL FINANCIAL STATEMENTS

Anavex Life Sciences Corp — balance sheet, income statement and cash flow trends

AVXLAnavex Life Sciences Corp

🇺🇸 USA · NASDAQ · Healthcare · Biotechnology

Value it Duel

Income Statement

Quarterly progression — trailing-twelve-month values

RevenueNet Income

Profit Funnel

Q4 2025 · TTM

Percentages are relative to revenue.

Key Figures

YoY change

Revenue0 $—

Gross Profit——

Operating Income-44.6 M $—

EBITDA-38.9 M $—

Net Income-39.9 M $—

Peer Comparison· Biotechnology

Company	Rev. Growth	Gross Margin	EBITDA Margin	Net Margin
AVXL	—	—	—	—
MSB	410.4%	-32.0%	-76.6%	-115.3%
RTALB	24.0%	35.1%	9.0%	136.3%
TLX	56.3%	50.8%	3.0%	-0.9%
Industry median	5.1%	84.0%	-105.8%	-125.7%

Company	Rev. Growth	Gross Margin	EBITDA Margin	Net Margin
AVXL	—	—	—	—
SGMT	—	—	—	—
NKTX	-100.0%	—	—	—
KPTI	6.3%	96.0%	-97.9%	-129.0%
RNA	312.4%	-275.6%	-1,108.5%	-1,076.9%
IMRX	-100.0%	—	—	—
Industry median	5.1%	84.0%	-105.8%	-125.7%

Balance Sheet

Quarterly period-end values

Total AssetsTotal LiabilitiesEquity

Capital Structure

Q4 2025

Equity126.6 M $93%
Current Liabilities6.4 M $5%
Long-term Liabilities2.9 M $2%

Key Figures

YoY change

Total Assets133 M $+7.2%

Total Liabilities6.4 M $-51.5%

Total Equity126.6 M $+14.2%

Cash & ST Investments131.7 M $+9.1%

Total Debt——

Net Debt-131.7 M $—

Peer Comparison· Biotechnology

Company	Current Ratio	Debt/Equity	NetDebt/EBITDA	Equity/Assets
AVXL	20.87	—	—	95.2%
MSB	—	—	—	—
RTALB	1.21	1.2%	0.90	84.9%
TLX	1.43	112.3%	13.13	35.1%
Industry median	5.90	10.9%	1.15	70.0%

Company	Current Ratio	Debt/Equity	NetDebt/EBITDA	Equity/Assets
AVXL	20.87	—	—	95.2%
SGMT	20.34	0.0%	2.27	95.1%
NKTX	12.96	26.2%	1.71	76.8%
KPTI	1.08	-86.9%	-0.95	-202.1%
RNA	13.04	1.1%	0.65	80.1%
IMRX	32.45	1.8%	-60.72	96.1%
Industry median	5.90	10.9%	1.15	70.0%

Cash Flow Statement

Quarterly progression — trailing-twelve-month values

Operating Cash FlowCapital ExpendituresFree Cash Flow

Cash Flow Bridge

Q4 2025 · TTM

Key Figures

YoY change

Operating Cash Flow-34.1 M $—

Capital Expenditures0 $—

Free Cash Flow-34.1 M $—

Dividends Paid——

Peer Comparison· Biotechnology

Company	CF Margin	FCF Margin	CapEx Ratio	CF/Net Income
AVXL	—	—	—	85.3%
MSB	-87.7%	-90.0%	2.3%	76.1%
RTALB	58.5%	88.6%	10.8%	42.9%
TLX	-2.2%	-6.3%	4.1%	243.1%
Industry median	-88.0%	-90.9%	1.9%	81.5%

Company	CF Margin	FCF Margin	CapEx Ratio	CF/Net Income
AVXL	—	—	—	85.3%
SGMT	—	—	—	91.3%
NKTX	—	—	—	87.3%
KPTI	-39.1%	-39.1%	0.0%	30.3%
RNA	-1,103.4%	-1,131.1%	27.7%	102.5%
IMRX	—	—	—	91.3%
Industry median	-88.0%	-90.9%	1.9%	81.5%

Amounts are in the company’s reporting currency. Peer comparison tables use ratio-based metrics so currency differences do not distort the picture.

Go deeper on AVXL

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Jul 2, 26. This content is for informational purposes only and is not investment advice.